Clinical Trials · NCT04184622
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 2,539
- Start date
- Dec 2019
- Locations
- 118 sites, 10 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight (Primary Treatment Period)